Enveric Biosciences
ENVB
24 hedge funds and large institutions have $737K invested in Enveric Biosciences in 2026 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 1
591% more capital invested
Capital invested by funds: $107K → $737K (+$630K)
118% more funds holding
Funds holding: 11 → 24 (+13)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
12.9% more ownership
Funds ownership: 1.49% → 14.39% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$432K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$240K |
| 3 |
Renaissance Technologies
New York
|
+$77K |
| 4 |
AC
Armistice Capital
New York
|
+$76.9K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$72.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$48.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.19K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$2 |
ENVB Hedge Fund Activity: Q2 2026 in Review
24 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2026, worth a combined $737K — up 591% from $107K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ENVB positions and 1 closed out — a net gain of 13 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $432K. The largest seller was Geode Capital Management, cutting an estimated $48.9K.
- 24 institutional investors held Enveric Biosciences (ENVB) as of Q2 2026, up from 11 in Q1 2026.
- Funds reported $737K of Enveric Biosciences stock for Q2 2026, up 591% quarter-over-quarter.
- 14 funds opened new Enveric Biosciences positions in Q2 2026 and 1 closed out, a net change of +13 holders.
- The largest Enveric Biosciences buyer in Q2 2026 was Sio Capital Management, an estimated $432K added.
- The largest Enveric Biosciences seller in Q2 2026 was Geode Capital Management, an estimated $48.9K sold.
Based on aggregated 13F filings for Q2 2026.